InvestorWire NewsRoom

Article

Hope of Herd Immunity Dwindles Alongside Federal COVID-19 Budget and Supplies; Aditxt Inc. (NASDAQ: ADTX) and AditxtScore(TM) Could Create Map to COVID-19 Immune Responses
June 24, 2022

Hope of Herd Immunity Dwindles Alongside Federal COVID-19 Budget and Supplies; Aditxt Inc. (NASDAQ: ADTX) and AditxtScore(TM) Could Create Map to COVID-19 Immune Responses

  • Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinated
  • The AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herd
  • No additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the fall months and uptick in virus counts
  • The reallocation of funds for further vaccine development has reduced the amount spent on testing efforts causing concern for epidemiologists due to the lack of variant tracking 

The COVID-19 pandemic, from the start, has been characterized by the high unpredictability of the virus. Despite the best efforts of the scientific community to use the historical data and patterns of previous viruses, it is becoming apparent that the original presumptions are no longer valid. The original hypothesis was that once enough people created an immunity to COVID-19, it would stop the virus dead in its tracks; unfortunately, what they are learning is that herd immunity is unlikely to happen. 

Herd immunity occurs when a virus can’t spread because it keeps encountering people who have become immune to the specific virus. The idea is that a small group of people lacking resistance to the virus can be protected by the immune herd because it is less likely to spread to them. Even though the mentality that herd immunity can be successful through immunizations, scientists no longer believe that this is an appropriate management strategy for COVID-19 long-term. 

Two years after a COVID-19 vaccine was made available, fewer than 70% of Americans are fully vaccinated (https://ibn.fm/lcOKY). The pockets of unvaccinated people who lack any type of immunity to this ever-changing virus only provide the potential for the virus to grow and mutate as it spreads. Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). The score can be used to provide those tested with important answers to questions like:

  • Are antibodies present?
  • How are these antibodies present – vaccine or natural immune system response?
  • Will this immunity status provide protection from the virus in the future?
  • What is the best approach to creating immunity for that individual?

“As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” Kevin Murdock, CEO of Premier Medical Laboratory Services, stated (https://ibn.fm/pbmD3). “With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them.”

With the potential for herd immunity off the table, and federal COVID funds dwindling, supply rationing has begun. Of the current budget, the Biden Administration has reallocated $5 billion to purchase updated versions of the vaccine for fall. Since Congress has approved no new funding, the Administration is forced to use the remaining budget to consider the longer-term solutions, like fall when virus uptick increases. At this time, epidemiologists are concerned about the blind spots created due to the shift in focus from testing to more vaccine development. Without the increased testing efforts, it becomes impossible to track and isolate variants. Without the funding, further development on the COVID-19 front will be less likely to be sustainable.

About Aditxt

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).